Iteos Therapeutics Net Worth
Iteos Therapeutics Net Worth Breakdown | ITOS |
Iteos Therapeutics Net Worth Analysis
Iteos Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Iteos Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Iteos Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Iteos Therapeutics' net worth analysis. One common approach is to calculate Iteos Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Iteos Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Iteos Therapeutics' net worth. This approach calculates the present value of Iteos Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Iteos Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Iteos Therapeutics' net worth. This involves comparing Iteos Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Iteos Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Iteos Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Iteos Therapeutics' net worth research are outlined below:
| Iteos Therapeutics generated a negative expected return over the last 90 days | |
| Iteos Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 12.6 M. Net Loss for the year was (112.64 M) with profit before overhead, payroll, taxes, and interest of 267.63 M. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (103.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iteos Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: BIOTECHNOLOGY VALUE FUND L P Increases Stake in ITeos Therapeutics Inc |
Iteos Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Iteos Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Iteos Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Iteos Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iteos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iteos Therapeutics backward and forwards among themselves. Iteos Therapeutics' institutional investor refers to the entity that pools money to purchase Iteos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 1.2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1 M | State Street Corp | 2024-06-30 | 963.9 K | Goldman Sachs Group Inc | 2024-06-30 | 732.3 K | Geode Capital Management, Llc | 2024-09-30 | 640.4 K | Renaissance Technologies Corp | 2024-09-30 | 536.4 K | K2 Principal Fund Lp | 2024-09-30 | 535 K | Candriam Luxembourg S.c.a. | 2024-06-30 | 509.3 K | Jpmorgan Chase & Co | 2024-06-30 | 462 K | Blackrock Inc | 2024-06-30 | 3.7 M | Ra Capital Management, Llc | 2024-09-30 | 3.2 M |
Follow Iteos Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 301.04 M.Market Cap |
|
Project Iteos Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.20) | (0.21) |
When accessing Iteos Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Iteos Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Iteos Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Iteos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iteos Therapeutics. Check Iteos Therapeutics' Beneish M Score to see the likelihood of Iteos Therapeutics' management manipulating its earnings.
Evaluate Iteos Therapeutics' management efficiency
Iteos Therapeutics has return on total asset (ROA) of (0.1304) % which means that it has lost $0.1304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1972) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.25 in 2024. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 122.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 3.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.08 | 8.28 | |
| Tangible Book Value Per Share | 16.08 | 8.28 | |
| Enterprise Value Over EBITDA | (0.97) | (1.02) | |
| Price Book Value Ratio | 0.68 | 0.65 | |
| Enterprise Value Multiple | (0.97) | (1.02) | |
| Price Fair Value | 0.68 | 0.65 | |
| Enterprise Value | 372.8 M | 454.1 M |
The management team at Iteos Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 1.2621 | Revenue 35 M | Quarterly Revenue Growth (1.00) | Revenue Per Share 0.906 | Return On Equity (0.20) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iteos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iteos Therapeutics Corporate Filings
13A | 21st of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Iteos Therapeutics Earnings per Share Projection vs Actual
Iteos Therapeutics Corporate Management
| Matthew Gall | Chief Officer | Profile | |
| Matthew MBA | Chief Officer | Profile | |
| Ryan Baker | Head Relations | Profile | |
| Joanne MD | Chief Officer | Profile | |
| Adi Osovsky | Executive Legal | Profile |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.